• LAST PRICE
    0.1761
  • TODAY'S CHANGE (%)
    Trending Down-0.0010 (-0.5647%)
  • Bid / Lots
    0.1700/ 5
  • Ask / Lots
    0.1830/ 15
  • Open / Previous Close
    0.1768 / 0.1771
  • Day Range
    Low 0.1531
    High 0.1775
  • 52 Week Range
    Low 0.0853
    High 3.5900
  • Volume
    1,030,306
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 0.1771
TimeVolumeGRTX
09:32 ET13790.177
09:38 ET51000.17595
09:43 ET2000.175
09:45 ET50000.1701
09:52 ET39430.1768
09:54 ET27420.1758
09:59 ET32970.1752
10:01 ET3000.176
10:03 ET2000.1767
10:06 ET4000.1766
10:08 ET305770.172
10:10 ET10500.1701
10:12 ET2000.1729
10:15 ET11750.1728
10:19 ET20000.1726
10:26 ET302380.169514
10:28 ET8000.1677
10:30 ET13000.1671
10:32 ET150000.1651
10:33 ET157000.165
10:35 ET58680.164799
10:37 ET42060.1649
10:39 ET2000.1649
10:46 ET108610.1649
10:48 ET7310.1644
10:50 ET620650.162
10:51 ET450000.1621
10:53 ET1000.1644
10:55 ET1504290.1575
10:57 ET111190.1618
11:00 ET103000.1618
11:02 ET7350.1618
11:04 ET170720.169
11:08 ET3000.1689
11:15 ET52000.168
11:20 ET10000.168799
11:22 ET1000.163
11:24 ET60000.1679
11:26 ET143160.164
11:27 ET1000.165
11:31 ET185000.1651
11:33 ET1000.1661
11:36 ET15000.166
11:38 ET8000.166
11:44 ET1000.166
11:47 ET1000.1661
11:49 ET156510.16605
11:54 ET113000.166
11:56 ET1000.165
12:00 ET511430.168
12:05 ET261000.17
12:09 ET818150.1705
12:20 ET2000.172
12:21 ET2000.172
12:23 ET2000.172
12:25 ET3250.173
12:27 ET1000.173
12:30 ET2000.173
12:32 ET2000.173
12:34 ET2000.1767
12:36 ET32000.1745
12:38 ET11000.1745
12:39 ET15750.1731
12:41 ET1000.173
12:43 ET60000.1731
12:54 ET1000.1731
12:56 ET130400.1731
12:59 ET1000.173
01:01 ET1000.173
01:03 ET8000.173
01:06 ET18000.173
01:08 ET2000.173
01:10 ET1000.173
01:12 ET82000.173
01:15 ET460000.1726
01:26 ET11200.173101
01:39 ET1000.173
01:44 ET1000.173
01:46 ET1000.173
01:50 ET1000.173
01:51 ET442640.173
01:53 ET1000000.173001
01:55 ET75820.173
01:57 ET1000.173
02:02 ET1000.173
02:04 ET1000.173
02:08 ET304000.1738
02:09 ET99000.173
02:13 ET35000.1725
02:18 ET90500.1775
02:20 ET12000.175
02:22 ET58840.175
02:26 ET1000.1775
02:29 ET3000.175
02:36 ET3000.175
02:38 ET1000.175
02:40 ET1000.1751
02:42 ET1000.1751
02:44 ET1000.1751
02:47 ET1140.1773
02:51 ET2000.175
02:54 ET2000.175
02:56 ET1000.175
03:02 ET5500.1772
03:09 ET10750.175
03:12 ET83440.1751
03:16 ET6500.1771
03:18 ET19750.1772
03:27 ET43000.1751
03:30 ET18000.17505
03:36 ET3000.17505
03:39 ET12000.17505
03:41 ET3000.17505
03:43 ET54000.1751
03:45 ET18000.1751
03:48 ET4140.175
03:50 ET63710.175
03:52 ET38550.175
03:54 ET2000.175
03:56 ET104760.1765
03:57 ET11000.1761
03:59 ET4000.1761
Data delayed at least 15 minutes.
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGRTX
Galera Therapeutics Inc
9.6M
-0.1x
---
United StatesEFTR
eFFECTOR Therapeutics Inc
9.5M
-0.1x
---
United StatesNCNA
NuCana PLC
7.6M
0.0x
---
United StatesBUDZ
Weed Inc
9.8M
-337.8x
---
United StatesASLN
Aslan Pharmaceuticals Ltd
9.3M
-0.1x
---
United StatesRNAZ
Transcode Therapeutics Inc
8.6M
0.0x
---
As of 2024-05-11

Company Information

Galera Therapeutics, Inc. is a biopharmaceutical company focused on developing a pipeline of novel, therapeutic candidates that have the potential to transform radiotherapy in cancer. The Company’s lead product candidate, avasopasem manganese (avasopasem), is a highly selective small molecule dismutase mimetic that the Company is developing for the reduction of severe oral mucositis (SOM) in patients with head and neck cancer (HNC), the reduction of esophagitis in patients with lung cancer, and the reduction of cisplatin-induced kidney damage in patients with cancer. The Company’s second product candidate, rucosopasem manganese (rucosopasem), is in development to augment the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Rucosopasem is an orphan drug designation and orphan medicinal product designation for the treatment of pancreatic cancer.

Contact Information

Headquarters
45 Liberty Blvd., Suite 230MALVERN, PA, United States 19355
Phone
610-725-1500
Fax
302-636-5454

Executives

Independent Chairman of the Board
Michael Powell
President, Chief Executive Officer, Director
J. Mel Sorensen
Chief Financial Officer, Secretary
Christopher Degnan
Chief Operating Officer
Robert Beardsley
Chief Legal & Compliance Officer and Secretary
Jennifer Stacey

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$9.6M
Revenue (TTM)
$0.00
Shares Outstanding
54.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.01
EPS
$-1.42
Book Value
$-2.41
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.